Adjuvant radioimmunotherapy trial with Lodine-131 - labeled anti - carcinoembryonic antigen monoclonal antibody F6 F(ab′)2 after resection of liver metastases from colorectal cancer

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3487-3493

  Ychou, Marc ^a,b,c,d   Azria, David ^a,b,c,d   Menkarios, Cathy ^d,g   Faurous, Patrick ^d   Quenet, François ^d   Saint Aubert, Bernard ^d   Rouanet, Philippe ^d   Pélegrin, Monique ^a,b,c,d   Bascoul Mollevi, Caroline ^d   Guerreau, Dominique ^e   Saccavini, Jean Claude ^e   Mach, Jean Pierre ^f   Artus, Jean Claude ^d   Pèlegrin, André ^a,b,c,d  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^b Inst Natl de la Sante et de la R   (France)

^c UNIV MONTPELLIER   (France)

^d CENTRE VAL D AURELLE   (France)

^e CIS Bio International   (France)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IODINE 131; CARCINOEMBRYONIC ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ADULT; ALLERGIC REACTION; ANOREXIA; ANTIBODY RESPONSE; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DEATH; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; IMMUNOREACTIVITY; ISOTOPE LABELING; LIVER METASTASIS; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RADIOACTIVITY; RADIOIMMUNOTHERAPY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; COLORECTAL TUMOR; IMMUNOLOGY; LIVER RESECTION; LIVER TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADENOCARCINOMA; ADULT; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOTHERAPY, ADJUVANT;

EID: 50349086793     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4698     Document Type: Article

References (34)

1. Scheele J. Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995;19:59-71.
2. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997:15: 938-46.
3. Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 1999:49:231 -55.
4. Lehnert T, Otto G, Herfarth C. Therapeutic modalities and prognostic factors for primary and secondary liver tumors. World J Surg 1995:19:252 -63.
5. Jaeck D, Bachellier P, Guiguet M, et al Long term survival following resection of colorectal hepatic metastases. Association Francaise de Chirurgie. Br J Surg 1997;84:977-80.
6. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006;24:4976-82.
7. Gayowski TJ, Iwatsuki S, Madariaga JR. et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 1994;116:703-10.
8. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63.
9. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine 1131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19: 3918-28.
10. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
11. Behr TM, Liersch T, Greiner-Bechert L, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 2002;94:1373-81.
12. Liersch T, Meller J, Kulle B, et al. Phase II trial of car-cinoembryonic antigen radioimmunotherapy with 1311-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 2005;23:6763-70.
13. Behr TM, Sharkey RM, Juweid ME, et al. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and anti-mucin monoclonal antibodies. J Nucl Med 1997:38: 409-18.
14. Welt S, Divgi CR, Kemeny N, et al. Phase l/ll study of iodine 131 -labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994:12:1561 -71.
15. Knox SJ, Goris ML,Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 2000;6:406-14.
16. Ychou M, Pelegrin A, Faurous P, et al. Phase-l/ll ra-dio-immunotherapy study with lodine-131-!abeled anti-CEA monoclonal antibody F6 F(ab′)2 in patients with non-resectable liver metastases from colorectal cancer. Int J Cancer 1998;75:615-9.
17. Hammarstrom S, Shively JE, Paxton RJ, et al. Antigenic sites in carcinoembryonic antigen. Cancer Res 1989;49:4852-8.
18. Ychou M, Ricard M, Lumbroso J, et al. Potential contribution of 1311-labelled monoclonal anti-CEA antibodies in the treatment of liver metastases from colorectal carcinomas: pretherapeutic study with dose recovery in resected tissues. Eur J Cancer 1993; 29:1105-11.
19. Buchegger F, Mach JP, Pelegrin A, et al. Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma. J Nucl Med 1995;36:420-9.
20. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000:47:13-47.
21. Welt S, Divgi CR, Real FX, et al. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol 1990;8:1894-906.
22. Bertagnolli MM. Radioimmunotherapy for colorectal cancer. Clin Cancer Res 2005;11:4637-8.
23. Sgouros G. Radioimmunotherapy of micrometasta-ses: sidestepping the solid-tumor hurdle. J Nucl Med 1995;36:1910-2.
24. Lygidakis NJ, Sgourakis G, VIachos L, et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepato-gastroenterology 2001;48:1685-91.
25. Asahara T, Kikkawa M, Okajima M, et al. Studies of postoperative transarterial infusion chemotherapy for liver metastasis of colorectal carcinoma after hepatectomy. Hepato-gastroenterology 1998:45: 805-11.
26. Rudroff C, Altendorf-Hoff mann A, Stangl R, Scheele J. Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after RO resection of colorectal liver metastases. Kongressbd Dtsch Ges Chir Kongr 1999;384:243-9.
27. Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998;228:756-62.
28. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002;20:1499-505.
29. Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 2005:352:734 - 5.
30. Mackay HJ, Billingsley K, Gallinger S, et al. A multi-center phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases. Am J Clin Oncol 2005;28:547-54.
31. Wong J Y, Shibata S, Williams LE, et al. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 2003;9:5842-52.
32. Liersch T, Meller J, Bittrich M, Kulle B, Becker H, Goldenberg DM. Update of carcinoembryonic antigen radioimmunotherapy with (131)i-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol 2007;14:2577-90.
33. Garambois V, Glaussel F, Foulquier E, et al. Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers. BMC Cancer 2004:4:75.
34. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823-34.